Disentangling The Interrelationship Between Multimordibity, Multimedicine Use, And Cardiovascular Health
Funder
National Health and Medical Research Council
Funding Amount
$480,978.00
Summary
Australians are living longer, but are also living with more health conditions and taking more medicines to treat those conditions. For people with cardiovascular disease (CVD), this is a problem as hundreds of non-cardiac medicines known to increase the risk of cardiovascular events, such as myocardial infarction, stroke, or heart failure. We will take a holistic, patient-centred approach determine the true burden of CVD related to use of medicines to treat comorbid conditions in Australia.
Centre Of Research Excellence In Medicines Intelligence
Funder
National Health and Medical Research Council
Funding Amount
$2,500,000.00
Summary
The NHMRC Centre of Research Excellence in Medicines Intelligence is a co-ordinated research program that will accelerate the development and translation of evidence on prescribed medicines use and outcomes for regulators and payers. The CRE is perfectly placed to embrace the national ‘call to action’ from the Health Minister's recent announcement to establish Quality Use of Medicine Safety as a National Health Priority.
Combating Escalating Harms Associated With Pharmaceutical Opioid Use
Funder
National Health and Medical Research Council
Funding Amount
$925,767.00
Summary
Increases in opioid use have been accompanied by increased opioid harms. But there is a lack of population-level evidence about drivers of long-term prescribed opioid use, dependence, overdose and other harms. Using linked data, we will fill these gaps using a cohort of all people in NSW prescribed opioids since 2002, linked to datasets containing information on health, social and health service utilisation, that will permit a comprehensive assessment of the risks of all prescribed opioids.
Post-market Surveillance Of Medicine-related Adverse Events
Funder
National Health and Medical Research Council
Funding Amount
$99,248.00
Summary
Observational studies using administrative data are an important complement to spontaneous reporting systems for detecting medicine-related adverse events after they go to market, as they reflect real-world use of medicines; yet, they require rigorous methodological approaches to avoid bias. This project will review the existing methodologies for detecting adverse events in administrative data and apply them to Australian data.
Centre Of Research Excellence In Medicines And Ageing
Funder
National Health and Medical Research Council
Funding Amount
$2,601,415.00
Summary
Medicines have an important place in health and are commonly used for long periods, sometimes life-long. Using medicines wisely requires a careful balance between benefits and harmful effects. Currently, there is limited information to guide medicines use over a lifetime. Using large linked datasets, the CRE in Medicines and Ageing will generate much needed evidence about real world medicines use to support clinical and pharmaceutical policy decisions.
ManagemenT Of ChronIc CardioMetabolic DiseasE And Treatment DiScontinuity In Adult ADHD PAtieNts (TIMESPAN)
Funder
National Health and Medical Research Council
Funding Amount
$499,613.00
Summary
The aim of TIMESPAN is to improve the management of patients with Attention Deficit Hyperactivity Disorders (ADHD) and co-occurring cardiometabolic disease (i.e. obesity, type-2 diabetes, and cardiovascular disease). Inadequate treatment of these common conditions can lead to premature death and substantial societal costs. We will use linked electronic health records and novel research methods to improve clinical outcomes and quality of life of adults with ADHD and cardiometabolic disease.
Improving Medication Safety In Seniors: A Cross-Jurisdictional Linkage Project
Funder
National Health and Medical Research Council
Funding Amount
$636,717.00
Summary
The project will identify priorities for tackling the current epidemic of hospitalisation of Australians aged 65+ years due to side effects of their medications. Two different groups of medications will be investigated. The first will be the prescribed drugs most often recorded as causes of hospital stay, including those taken to stop blood clotting, for high blood pressure and other cardiovascular problems, for rheumatism or strong pain relief, anti-cancer drugs and steroids. The study will exa ....The project will identify priorities for tackling the current epidemic of hospitalisation of Australians aged 65+ years due to side effects of their medications. Two different groups of medications will be investigated. The first will be the prescribed drugs most often recorded as causes of hospital stay, including those taken to stop blood clotting, for high blood pressure and other cardiovascular problems, for rheumatism or strong pain relief, anti-cancer drugs and steroids. The study will examine which of these drugs taken under what circumstances has the highest risk, so prevention can be better targeted. The study will investigate if adequate laboratory monitoring of the anti- clotting drugs is taking place and whether the guidelines should be updated. The second group will be 68 medications that should be avoided in seniors according to an international expert panel. The research will see how often these 'inappropriate medications' are still prescribed in the Australian setting, and the size of their contributions to unplanned hospital stays. The researchers suspect that this problem is much larger than immediately apparent from routine statistics, because many of the side effects of inappropriate medications are non-specific, such as confusion, drowsiness or difficulty standing up, thus putting seniors at risk of falls and neglect of other aspects of their health. The study will use a unique and new Australian research facility, which has brought together health data on the entire population of WA from both the State and Commonwealth levels, including information on pharmaceuticals, Medicare use, hospital stays and deaths. The facility works in such a way as to preserve patient and GP privacy. A strong feature of this research will be the degree of involvement of a representative and voluntary group of older Australian patients who attend GP clinics, and the GPs themselves, in advising the researchers on what's important to consumers and GPs.Read moreRead less